Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

299 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Quantitative assessment of finger motor impairment in multiple sclerosis.
Bonzano L, Sormani MP, Tacchino A, Abate L, Lapucci C, Mancardi GL, Uccelli A, Bove M. Bonzano L, et al. Among authors: uccelli a. PLoS One. 2013 May 31;8(5):e65225. doi: 10.1371/journal.pone.0065225. Print 2013. PLoS One. 2013. PMID: 23741485 Free PMC article.
Isolated cognitive relapses in multiple sclerosis.
Pardini M, Uccelli A, Grafman J, Yaldizli Ö, Mancardi G, Roccatagliata L. Pardini M, et al. Among authors: uccelli a. J Neurol Neurosurg Psychiatry. 2014 Sep;85(9):1035-7. doi: 10.1136/jnnp-2013-307275. Epub 2014 Mar 31. J Neurol Neurosurg Psychiatry. 2014. PMID: 24686566
Dramatic rebounds of MS during pregnancy following fingolimod withdrawal.
Novi G, Ghezzi A, Pizzorno M, Lapucci C, Bandini F, Annovazzi P, Mancardi GL, Uccelli A. Novi G, et al. Among authors: uccelli a. Neurol Neuroimmunol Neuroinflamm. 2017 Jul 27;4(5):e377. doi: 10.1212/NXI.0000000000000377. eCollection 2017 Sep. Neurol Neuroimmunol Neuroinflamm. 2017. PMID: 28804745 Free PMC article. No abstract available.
No evidence of disease activity (NEDA-3) and disability improvement after alemtuzumab treatment for multiple sclerosis: a 36-month real-world study.
Prosperini L, Annovazzi P, Boffa L, Buscarinu MC, Gallo A, Matta M, Moiola L, Musu L, Perini P, Avolio C, Barcella V, Bianco A, Farina D, Ferraro E, Pontecorvo S, Granella F, Grimaldi LME, Laroni A, Lus G, Patti F, Pucci E, Pasca M, Sarchielli P; Italian Alemtuzumab Study Group. Prosperini L, et al. J Neurol. 2018 Dec;265(12):2851-2860. doi: 10.1007/s00415-018-9070-x. Epub 2018 Sep 26. J Neurol. 2018. PMID: 30259178
299 results